Retatrutide is not available by prescription yet. Eli Lilly has said it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027. With a standard FDA review, a decision would most likely come in late 2027, or around mid-2027 at the earliest if the FDA grants a faster priority review. Until then, the only legitimate ways to receive it are a clinical trial or Lilly’s limited early access program.

Key facts

• Today (Oct 2026): investigational, not FDA-approved, not sold by any pharmacy.
• FDA submission: planned for Q1 2027 (Lilly, July 23, 2026).
• Typical review: about 10 to 12 months standard, about 6 to 8 months with priority review.
• Most likely approval window: late 2027 to early 2028, if the FDA approves it.
• Early access: opened by Lilly in August 2026 for a narrow group of patients with severe obesity, requested by their physician.

The timeline, step by step

• 2023: Phase 2 results show about 24% average weight loss at 48 weeks.
• Dec 2025: TRIUMPH-4 (knee osteoarthritis) is the first Phase 3 trial to report: 28.7% at 12 mg.
• May 21, 2026: TRIUMPH-1, the main obesity trial, reports topline results: 28.3% at 12 mg over 80 weeks among people who stayed on treatment.
• July 23, 2026: TRIUMPH-2 and TRIUMPH-3 succeed; Lilly sets the FDA submission for Q1 2027.
• Aug 3, 2026: Lilly confirms an early access program.
• Sept 29, 2026: full TRIUMPH-1 results published in the New England Journal of Medicine: 25.0% at 12 mg, counting everyone who started, vs 3.9% on placebo.
• Sept 30, 2026: full TRIUMPH-2 results presented at EASD and published in The Lancet.
• Q1 2027: planned BLA submission.
• Late 2027 to 2028: possible FDA decision.

Why “biologic” and why the wait?

Retatrutide is a large peptide, and Lilly is filing it as a biologic. The company moved its submission from 2026 into early 2027 to complete manufacturing and quality-control data the FDA requires. That is a normal part of bringing a new medicine to market at scale, not a sign that the trials went badly. The trial results have been consistently positive.

The early access program

Lilly’s early access program is real but narrow. Based on public reporting, it is generally for adults who:

• cannot enroll in a clinical trial,
• have severe obesity with two or more serious complications, and
• have already tried, or discussed, the standard approved treatments.

A physician has to request it. Doctors have reported that the process is slow and not very transparent, so it is not a practical route for most people.

What about “research retatrutide” sold online?

Websites selling “research retatrutide” or “for research use only” vials are not selling the medicine tested in the TRIUMPH trials. Their products are not FDA-approved, not made under the manufacturing controls the trials relied on, and not checked for purity, dose or sterility. Retatrutide also cannot be legally compounded by pharmacies while it is an unapproved investigational drug. The honest answer for anyone interested is to wait for approval, or ask a doctor about trials.

What you can do today

The good news: the approved medicines in the same family, tirzepatide and semaglutide, already produce substantial weight loss and are available now through licensed providers. See Retatrutide vs tirzepatide vs semaglutide, How GLP-1 telehealth works, and our legal status tracker, which we update when the FDA acts.

Sources

• Jastreboff et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med, Sept 29, 2026
• BioPharma Dive: Lilly, with new data, to seek FDA approval of retatrutide (Jul 23, 2026)
• AJMC: Lilly expands retatrutide access amid doctor pushback
• TCTMD: TRIUMPH-1 results
• Pharmacy Times: TRIUMPH-2 results
• Eli Lilly: TRIUMPH-4 topline results

Educational content only, not medical advice. Retatrutide is an investigational medicine and is not FDA-approved.

← All articles